Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
The STEP 1 trial for semaglutide showed that participants lost an average of 14.9 percent of body weight, but lean mass accounted for roughly 40 percent of the total weight lost
The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Trial SOUL (McGuire et al., NEJM 2025) Design Phase 3 / event-driven Population Adults with T2D + ASCVD or CKD Key result Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D
Address: B 117 Okhla industries Area Phase -I New Delhi / B-289, Okhla industrial Area, phase-1, New Delhi, 110020, India Vendor Details Country of origin: India 799 MRP 8597% off Save more with additional offers Flat Rs.150 on a Min Transaction of Rs.1000
US$ 19.98
US$ 20.83
US$ 24.00
